Levetiracetam for Benign Rolandic Epilepsy

Efficacy of Levetiracetam for Language Dysfunction Associated With Benign Epilepsy With Centrotemporal Spikes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00181116

Enrollment

Registered

2005-09-16

Start date

2005-03-31

Completion date

2006-09-30

Last updated

2009-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Epilepsy, Benign rolandic, Levetiracetam

Brief summary

This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.

Detailed description

This is a 6 month study in which children on another anticonvulsant would have EEG, language testing, and a clinic visit at baseline. They would then be rapidly transitioned off of their current anticonvulsant and onto levetiracetam (Keppra). Repeat EEG and language testing would be done after 6 months to evaluate for improvement.

Interventions

DRUGLevetiracetam

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Ages 6-12 * Benign rolandic epilepsy * Language difficulties as reported by parents or teachers * On another anticonvulsant other than levetiracetam

Exclusion criteria

* Prior use of levetiracetam * On 2 or more anticonvulsants * Language problems prior to epilepsy * Another seizure disorder * Status epilepticus within the past 6 months * Significant psychiatric disease * Progressive neurologic disease

Design outcomes

Primary

Measure	Time frame
Language improvement	—

Secondary

Measure	Time frame
Seizure control	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026